Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives - Episode 6

Optimal Strategies for Navigating Referral and Bridging Therapy for CAR T-Cell Therapy in R/R DLBCL Patients

,

Experts discuss when a patient should be referred from community practice to an academic or specialized program, the factors influencing the choice and timing of bridging therapy before CAR T infusion, and how bridging therapy is coordinated between academic and community settings.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Integrating CAR T-Cell Therapy Into the Treatment Landscape for R/R DLBCL
    EP. 2: Bispecific Antibodies vs CAR T-Cell Therapy: Treatment Selection and Sequencing in Later-Line R/R DLBCL
    EP. 3: Selecting Candidates for CAR T-Cell Therapy in R/R DLBCL: Patient Characteristics, Eligibility, and Timing Considerations
    EP. 4: Expert Insights for Approaching Patient Counseling for CAR T-Cell Therapy in R/R DLBCL
    EP. 5: Practical Realities of CAR T-Cell Therapy for R/R DLBCL: Challenges and Lessons From the Community
    Now Viewing
    EP. 6: Optimal Strategies for Navigating Referral and Bridging Therapy for CAR T-Cell Therapy in R/R DLBCL Patients

    Video content above is prompted by the following:

    • At what point should a patient be referred from community practice to an academic or specialized program?
    • What factors influence your choice and the timing of bridging therapy relative to planned CAR T infusion? 
    • How do you coordinate bridging therapy, and is it typically done in the academic or community setting in your clinical practice?
    x